BioPharma Dive

@BioPharmaDive

We provide business journalism and in-depth insight into the most impactful news and trends shaping biotech and pharma. Sign up here:

Washington, D.C.
Vrijeme pridruživanja: srpanj 2013.

Tweetovi

Blokirali ste korisnika/cu @BioPharmaDive

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @BioPharmaDive

  1. prije 14 sati

    hopes to replicate its past success in quickly advancing a treatment for Ebola. But, as that experience showed, proving a new antiviral isn't easy.

    Poništi
  2. prije 15 sati

    acknowledged the cell therapy developer is worth less than it once thought, cutting the accounting value for research assets it acquired by $800M

    Poništi
  3. prije 15 sati

    With $200M more in bank, also in-licensed an experimental next-generation food allergy therapy from

    Poništi
  4. prije 16 sati

    A yet-to-be-named new company will house 's women's health, biosimilar and legacy drugs, providing space and resources for the pharma's higher-growth businesses.

    Poništi
  5. 4. velj

    Anteros Pharmaceuticals is the first company made via a partnership between and biotech accelerator BioMotiv. Its initial targets are liver and lung fibrosis, with one specific focus being IPF.

    Poništi
  6. 4. velj

    , and were the most active, collectively raising list prices on some 450 drugs this Jan., according to one Wall Street analyst.

    Poništi
  7. 4. velj

    HHS and previously worked together on an experimental Ebola treatment that proved effective in the 2018 outbreak of that disease.

    Poništi
  8. 3. velj

    's next challenge will be securing insurance coverage as people allergic to peanuts still have to avoid exposure to the food.

    Poništi
  9. 3. velj

    With biologics driving growth, is looking to diversify with a $315M purchase that hands it a slate of production sites.

    Poništi
  10. 3. velj

    Research into preventive treatments will continue, however, as an NIH leader declared a vaccine "essential" to ending the widespread disease.

    Poništi
  11. 3. velj

    will work with Chinese authorities to test its drug remdesivir, while is providing its adjuvant platforms to groups partnered with CEPI.

    Poništi
  12. 31. sij

    With $420M in Q4 revenues, 's cystic fibrosis drug Trikafta performed 5x better than expected — and capped off an 8-year growth story for the biotech's CEO.

    Poništi
  13. 31. sij

    Too few women and people of color are in executive positions or on the boards of biotech companies, according to a new report from BIO.

    Poništi
  14. 31. sij

    Competition is heating up for copycats to 's top-selling cancer drugs, as the U.S. biosimilar market shows some modest signs of shifting

    Poništi
  15. proslijedio/la je Tweet
    31. sij

    If you haven't yet, check out 's latest deep dive. After years being all-in on brain drugs, big pharma pulled back. Is a return on the horizon? And, if so, what effects might it have on drug research?

    Prikaži ovu nit
    Poništi
  16. 30. sij

    Spinraza rivals and Tecfidera patent challenges were in the spotlight as provided few details about its planned filing for aducanumab.

    Poništi
  17. 30. sij

    's top scientist, however, set low expectations the drug will show a clear benefit.

    Poništi
  18. 29. sij

    Biotech execs see a new era of neuroscience advances ahead. But it's hard to pinpoint what would cause pharma to dive back in — and what ripples that would create.

    Poništi
  19. 29. sij

    The Third Rock-backed company put an acting executive in place as it repositions for development in gene therapy and regenerative medicine.

    Poništi
  20. 29. sij

    Another 100 infants received ' Zolgensma in the fourth quarter, supported by broad insurance coverage and more newborn screening.

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·